Reata Pharma (RETA) Tops Q1 EPS by 82c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
May 10, 2022 6:40 AM EDTCompleted Rolling Submission of NDA for Omaveloxolone for Treatment of Patients with Friedreichs Ataxia; Actively Preparing for Commercial Launch
Updates Outcome of Type A Meeting with the FDA on the Protocol Amendment for FALCON
Reaffirms Cash Runway Through end of 2024
Conference Call with Management on May 10, 2022, at 8:30 a.m. ET
PLANO, Texas--(BUSINESS... More
